Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Salivary Gland Neoplasms × Maytansine × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Salivary Gland Neoplasms 1

Interventions

Carboplatin 3 trastuzumab deruxtecan 2 Docetaxel 2 Cisplatin 2 zanidatamab 1 sacituzumab govitecan 1 pembrolizumab 1 entrectinib 1 dehydroftorafur 1 ceralasertib 1 Specimen Handling 1 Sorafenib 1 Radiation 1 Platinum 1 Oral Hygiene 1 Maytansine 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Fluorouracil 1 Disulfides 1 Cetuximab 1 Biopsy 1 Bevacizumab 1 Ado-Trastuzumab Emtansine 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04620187 2026-02-24

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Dana-Farber Cancer Institute

Phase 2 Recruiting

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡